Press releases
- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
More ▼
Key statistics
As of last trade Halozyme Therapeutics Inc (RV7:FRA) traded at 39.49, -6.00% below its 52-week high of 42.01, set on May 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.49 |
---|---|
High | 39.49 |
Low | 39.49 |
Bid | 39.42 |
Offer | 39.70 |
Previous close | 40.21 |
Average volume | 126.44 |
---|---|
Shares outstanding | 127.27m |
Free float | 125.86m |
P/E (TTM) | 17.82 |
Market cap | 5.48bn USD |
EPS (TTM) | 2.42 USD |
Data delayed at least 15 minutes, as of May 29 2024 07:17 BST.
More ▼